Ser2039
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser2039  -  p300 (human)

Site Information
GLGQVGIsPLKPGTV   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 31828207

In vivo Characterization
Methods used to characterize site in vivo:
[32P] ATP in vitro ( 1 ) , flow cytometry ( 1 ) , immunoassay ( 1 ) , immunoprecipitation ( 1 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
lung cancer ( 1 )
Relevant cell line - cell type - tissue:
CL1-0 (pulmonary) ( 1 ) , CL1-5 (pulmonary) ( 1 ) , E.coli (bacterial) ( 1 ) , HeLa (cervical) ( 1 )

Upstream Regulation
Putative in vivo kinases:
CDK1 (human) ( 1 ) , ERK1 (human) ( 1 ) , ERK2 (human) ( 1 )
Kinases, in vitro:
CDK1 (human) ( 1 )
Treatments:
cycloheximide ( 1 ) , nocodazole ( 1 ) , seliciclib ( 1 ) , siRNA ( 1 ) , U0126 ( 1 )

Downstream Regulation
Effects of modification on p300:
acetylation ( 1 ) , protein degradation ( 1 )
Effects of modification on biological processes:
carcinogenesis, induced ( 1 ) , cell cycle regulation ( 1 ) , cell growth, induced ( 1 ) , cell motility, induced ( 1 ) , chromatin organization, altered ( 1 ) , transcription, inhibited ( 1 )

Disease / Diagnostics Relevance
Relevant diseases:
lung cancer ( 1 )

References 

1

Wang SA, et al. (2014) Phosphorylation of p300 increases its protein degradation to enhance the lung cancer progression. Biochim Biophys Acta 1843, 1135-49
24530506   Curated Info